GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Melpida overview
Melpida is under development for the treatment of spastic paraplegia type 50 (SPG50). The therapeutic candidate comprises recombinant adeno-associated virus (serotype 9) encoding a codon optimized human AP4M1 transgene (hAP4M1opt). It is administered through intrathecal route.
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
Elpida Therapeutics overview
Elpida Therapeutics is a biotechnology research company that delivers gene therapies to patients and offers toxicology plasmid, clinical trials, cell culture and cell therapy products. The company is headquartered in Los Angeles, California, the US.
For a complete picture of Melpida’s drug-specific PTSR and LoA scores, buy the report here.
